Cemiplimab for Non-Small Cell Lung Cancer

This trial tests cemiplimab, a medication for individuals with early-stage non-small cell lung cancer that can be surgically removed. The researchers aim to determine how much of the tumor remains after treatment with cemiplimab before surgery. Participants will receive cemiplimab both before and after surgery and may also receive chemotherapy if needed. This trial suits those diagnosed with stage II to IIIA non-small cell lung cancer with a PD-L1 level of at least 50%, and whose cancer can be surgically removed. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.

The trial does not specify if you need to stop taking your current medications. However, if you are on ongoing corticosteroid therapy above a certain dose, you may need to adjust it before starting the trial. It's best to discuss your specific medications with the trial team.

Research has shown that cemiplimab, a medicine that aids the immune system in fighting cancer, is generally safe for treating non-small cell lung cancer. Studies have found that patients with high levels of the protein PD-L1, which can affect the immune response to cancer, usually tolerate cemiplimab well. In one study, serious side effects occurred in about 38% of patients taking cemiplimab, compared to about 54% of those who only received chemotherapy. This indicates that while cemiplimab can cause side effects, they occur less frequently than with some other treatments.

Cemiplimab is unique because it harnesses the power of the immune system to fight non-small cell lung cancer in a way that's different from traditional chemotherapy. Unlike standard treatments that directly target cancer cells with chemicals, cemiplimab is an immune checkpoint inhibitor. It works by blocking a specific protein called PD-1, effectively unleashing the body’s immune response to attack cancer cells more aggressively. Researchers are excited about cemiplimab because it offers a promising alternative that may enhance the effectiveness of treatment both before and after surgery, potentially improving patient outcomes.

Studies have shown that cemiplimab can effectively treat non-small cell lung cancer, particularly in patients with high levels of the protein PD-L1. In a major study, patients taking cemiplimab lived a median of 26.1 months, compared to 13.9 months for those receiving chemotherapy. Another study found that 46.5% of patients experienced their cancer shrinking or remaining stable. These results suggest that cemiplimab could be a promising option for extending the lives of lung cancer patients. Additionally, it generally causes fewer severe side effects. In this trial, participants will receive perioperative cemiplimab, which includes neoadjuvant and adjuvant treatment phases, potentially combined with histology-matched adjuvant chemotherapy.¹²⁴⁶⁷